BMDC displayed enhanced Syk and Erk phosphorylation compared to WT BMDC. Furthermore, Ptpn22
R619W BMDC (orthologue of human Ptpn22 R620W ) exhibited a similar enhancement in IL-1β secretion and induced enhanced T-cell dependent IL-17 responses in vivo, indicating that the PTPN22 polymorphism behaves as a loss-of-function allele in the context of dectin-1 signals. Conclusions: Data highlight Ptpn22 as a novel regulator of dectin-1 signals and provide a link between genetically conferred perturbation to innate receptor signalling pathways and autoimmunity. References: Background: The urate transporters are one of the genetic determinants of serum uric acid concentrations. Common dysfunctional variants of ABCG2 are revealed to be a major cause of gout and hyperuricemia by decreasing urate excretion. In this study we describe the analysis of allelic variants in the ABCG2 in a cohort with primary gout. Objectives: The cohort was recruited in the Institute of Rheumatology, Prague. Gouty arthritis was diagnosed in 146 subjects (132 men, 14 women) according to the American college of rheumatology criteria 1977. Patients suffering from secondary gout and other purine metabolic disorders associated with pathological concentrations of serum uric acid were excluded. Methods: In each patient, the family history of gout, number of gouty attacks, the presence of tophi, the occurrence of associated diseases and therapy have been assessed. All 16 exons of ABCG2 were amplified using PCR, and sequenced directly. Results: In the ABCG2 gene, 19 intronic sequence variants were detected. In the case of c.689+1G>A, related to an individual with severe gouty phenotype, two abnormal splicing variants were identified: a) r. All these allelic variants were in silico predicted as a probably damaging. The p.Q141K, previously functionally characterized allelic variant with a strong effect on uric acid secretion impairment, was in cohort of gout patients presented with significantly higher minor allele frequency 0.24 (MAF), 57 heterozygotes/6 homozygotes, than in population of European origin (MAF=0.09) and world-wide population (MAF=0.12). In our cohort, the age of onset of gout had a normal distribution. Remarkably, in 75% of all individuals with early onset of gout between age 10-20 years, we detected allelic variant p.Q141K (in 6 out of 8 patients). In the age group 21-30 years, this allelic variant was detected in 42% of patients (8/19), and in the age group 61-70 years, just in 29% (13/29). Conclusions: Our results show that genetic factor ABCG2 should be considered as one of the strong common risks for gout. In summary, we revealed that allelic variants of ABCG2, especially dysfunctional variant p.Q141K, have a significant effect on earlier onset of gout. Background: The treatment of rheumatic diseases can be both expensive and ineffective with up to 1/3 of patient's failing to respond to current treatments. There is therefore a need to identify new treatments and to target these to individual patients. Although genetic studies have been successful in identifying common variation associated with disease susceptibility, a large proportion of these lie outside protein-coding regions. Many show enhancer activity but it is often unclear which gene(s) they regulate and how they contribute to disease. Chromatin folding brings linearly distant areas of the genome, such as promoters and enhancers, into close proximity, driving gene expression. Capture Hi-C (CHi-C) interrogates these interactions in a high-throughput, high-resolution manner, linking implicated enhancers to causal genes. Objectives: Utilising our existing CHi-C data on 3 rheumatic diseases, RA, JIA and PsA, targeting all known genetic associations, we explored the potential to identify candidate causal genes that are targets for existing drugs, which could be repositioned for use in these diseases. Methods: Chromatin interaction data for T-and B-cells in the 3 diseases was analysed using CHiCAGO v2 using a score cut-off of ≥5. Interactions between disease regions and promoters were identified using BEDTOOLS v2.21.0 and intersected with drug targets from DrugBank v4.5.0. Existing treatments for each disease were identified by the presence of the relevant name in the "indication" field. Results: Overall 850 genes were identified as interacting with a disease associated region. Of these, 61 are existing drug targets (303 drugs) (Table 1) and 9 are existing therapies used in the treatment of disease, primarily RA. Conclusions: Our study identifies genes which are implicated in disease, are the target of existing drugs and offer the potential for drug repositioning. Of the potential drugs identified for RA, 14 are used in the treatment of various cancers and 11 are used in the treatment of diabetes and multiple sclerosis. Interestingly, 17 potential drugs identified for PsA are used in the treatment of schizophrenia and 11 in the treatment of hypertension. This data shows a novel insight into how functional annotation of genetic associations in rheumatic diseases can provide gene targets for re-positioned therapies.
